Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers

Overview of attention for article published in BMC Medicine, March 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

blogs: 1 blog
twitter: 10 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 25 Dimensions

Readers on

mendeley: 55 Mendeley

Summary Blogs X Facebook Dimensions citations

So far, Dimensions has found 25 publications that cite this research output.

25

The most recent citing publications are shown below. View all 25 publications that cite this research output on Dimensions.

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer

Article in Cancers (May 2021)

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer

Article in Scientific Reports (February 2021)

CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer

Article in Cancer Treatment Reviews (December 2020)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.